Compare IPI & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | CAPR |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.6M | 324.6M |
| IPO Year | 2008 | N/A |
| Metric | IPI | CAPR |
|---|---|---|
| Price | $25.35 | $5.37 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $23.00 | ★ $23.17 |
| AVG Volume (30 Days) | 155.0K | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $222,728,000.00 | $11,130,509.00 |
| Revenue This Year | $10.01 | N/A |
| Revenue Next Year | N/A | $7,894.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $20.86 | $4.30 |
| 52 Week High | $39.01 | $20.75 |
| Indicator | IPI | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 43.92 |
| Support Level | $24.36 | $4.30 |
| Resistance Level | $25.34 | $6.01 |
| Average True Range (ATR) | 0.90 | 0.55 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 36.10 | 47.54 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, which is also the location of the firm's production facilities.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.